Most Read Articles
01 Sep 2016
Digoxin, as a new or preexisting therapy, does not increase mortality following acute phase of ST-elevation myocardial infarction (STEMI), as shown in the MAGIC study.
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
22 Mar 2017
Patients often seek consultation at the pharmacy for superficial skin infection. The goal of this activity is to improve pharmacists' knowledge on strategies to manage bacterial skin infection.
 
Please click here to access this module
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

Topical capsaicin as effective as oral agents for pain relief in PDPN

17 May 2017

The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.

Researchers searched multiple electronic databases for randomized controlled trials assessing the efficacy and safety of ≥4 weeks treatment with capsaicin 8% patch vs oral, centrally acting agents (ie, pregabalin, gabapentin, duloxetine, amitriptyline) in patients with PDPN.

Efficacy outcomes were the proportions of patients with ≥30 and ≥50 percent reductions in pain. Tolerability outcomes included somnolence, dizziness, nausea, diarrhoea, constipation, headache, fatigue, insomnia and rate of discontinuation due to adverse events (AEs).

A Bayesian method was applied to analyse aggregate-level data, and fixed and random effects models were estimated.

Pooled data from 25 randomized controlled trials showed that the capsaicin patch was superior to placebo with respect to ≥30 percent pain reduction (odds ratio [OR], 2.28; 95 percent CI, 1.19 to 4.03). The patch also demonstrated a numerical advantage compared with pregabalin (OR, 1.83; 0.91 to 3.34) and gabapentin (OR, 1.66; 0.74 to 3.23), and had similar efficacy compared with duloxetine (OR, 0.99; 0.5 to 1.79). There was not enough evidence to assess the relative efficacy of amitriptyline. For the more stringent outcome of ≥50 percent pain reduction, the patch showed a numerical advantage vs placebo but similar efficacy vs oral agents.

For tolerability, the capsaicin patch was only evaluated for headache as the incidence for other outcomes was 0 percent. On the other hand, oral, centrally acting agents had a significantly increased risk of somnolence (pregabalin, gabapentin, duloxetine and amitriptyline), dizziness (pregabalin, gabapentin, duloxetine and amitriptyline), nausea (duloxetine), diarrhoea (duloxetine), fatigue (duloxetine) and discontinuation because of AEs (pregabalin, gabapentin and duloxetine) as compared with placebo. Duloxetine, relative to pregabalin and gabapentin, had a significantly lower risk of dizziness but a significantly higher risk of nausea.

The present network meta-analysis provides insight into the relative efficacy of the capsaicin 8% patch vs oral, centrally acting agents recommended by the National Institute For Health and Clinical Excellence in UK (ie, pregabalin, duloxetine, gabapentin) in the treatment of patients with PDPN, researchers said. Findings suggest that the patch is as effective as duloxetine—which is recommended as a treatment of choice for PDPN in most clinical guidelines—in terms of delivering pain relief.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Sep 2016
Digoxin, as a new or preexisting therapy, does not increase mortality following acute phase of ST-elevation myocardial infarction (STEMI), as shown in the MAGIC study.
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
22 Mar 2017
Patients often seek consultation at the pharmacy for superficial skin infection. The goal of this activity is to improve pharmacists' knowledge on strategies to manage bacterial skin infection.
 
Please click here to access this module
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.